Eli Lilly to Invest $3 Billion in China, Seeks Approval for Weight Loss Pill

Lilly unveils $3 billion production expansion in China

The Zepbound developer is joining other drugmakers’ rush into China as it plans to boost its oral solid dosage supply chain to support the launch of its obesity pill orforglipron.

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

Eli Lilly to invest $3 billion in China, seeks approval for weight loss pill

Eli Lilly plans to invest $3 billion in China over the next decade, which ​will help build production capacity for its experimental ‌type-2 diabetes and obesity treatment orforglipron, the U.S. drugmaker said in a statement on Wednesday.

Lilly to Invest $3 Billion in China to Boost Obesity Pill

Eli Lilly & Co will invest $3 billion in China over the next decade to expand local production, with a focus on weight loss as the US drugmaker looks to cement its dominance in the booming obesity market.

Eli Lilly Plans $3B Investment to Expand Next-Gen GLP-1 Weight-Loss Production in China

On March 12, a major US pharmaceutical company announced intentions to invest $3 billion over the next decade to significantly expand its supply chain capacity in China. This investment aims to increase production of its next-generation oral medication, a small molecule GLP-1 receptor agonist currently awaiting regulatory approval in the country. The company plans to collaborate with local Chinese manufacturers to ramp up production of the drug,…

Weight-Loss Drug Giant Eli Lilly Announces $3B Expansion Plan in China - YT FINANCE

The post Weight-Loss Drug Giant Eli Lilly Announces $3B Expansion Plan in China appeared first on YT FINANCE.